PAN 006
Alternative Names: PAN-006Latest Information Update: 24 Feb 2022
At a glance
- Originator Pantherna Therapeutics
- Class Anti-inflammatories; RNA
- Mechanism of Action TIE-2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Adult respiratory distress syndrome
Highest Development Phases
- Preclinical Adult respiratory distress syndrome
Most Recent Events
- 15 Feb 2022 PAN 006 is available for licensing as of 15 Feb 2022 (Pantherna Therapeutics pipeline, February 2022)
- 15 Feb 2022 Preclinical trials in Adult respiratory distress syndrome in Germany (Parenteral) (Pantherna Therapeutics pipeline, February 2022)